ALI-LENA® Injection (lenacapavir) registered in Lao PDR
The Food and Drug Department has registered ALI-LENA® Injection (lenacapavir) 463.5 mg / 1.5 mL for subcutaneous use, indicated with other antiretrovirals for heavily treatment-experienced adults with multidrug-resistant HIV-1.
A Driving Force in Southeast Asian Pharmaceutical Manufacturing
Alliance’s first-half 2026 highlights, from ASEAN expansion to advanced biopharmaceutical manufacturing.
ALIVOSO® (vosoritide) registered in Lao PDR
The Food and Drug Department has registered ALIVOSO® (vosoritide) 1.2 mg powder for injection, indicated to increase linear growth in children with achondroplasia whose growth plates have not closed.
Official Notice Regarding Counterfeit ALI-TIRZEP® Products
Alliance Pharmaceutical Co., Ltd. has identified counterfeit products being distributed under the ALI-TIRZEP® name. How to identify them, how to verify genuine product, and how to report a suspected counterfeit.
ALI-TIRZEP® (tirzepatide) registered in Lao PDR across eight presentations
The Food and Drug Department has issued certificates of drug registration for ALI-TIRZEP® (tirzepatide) in eight presentations — four single-dose and four multi-dose — manufactured by Alliance Pharmaceutical Co., Ltd in Vientiane Capital.
Alliance and Mane Group sign 50/50 joint venture to establish PHANNTHAMIT in Cambodia
Laos Alliance Pharmaceutical Group and Cambodia’s Mane Group have signed a 50/50 joint venture to establish PHANNTHAMIT Co., Ltd — a new pharmaceutical and healthcare company serving all 25 provinces of Cambodia and Phnom Penh.
